Resources

Ten Mistakes to Avoid when Searching Gene Sequences

Avoid the costly pitfalls of inaccurate, irrelevant, and untimely search results - what you need to consider before your next search.
Learn More»

The value of a cost-effective informatics platform that enables rapid and relevant search of the vast universe of sequences and their patents with regard to commercialization of new drugs cannot be understated. This is particularly true in the fast-paced R&D area of infectious disease research. We selected GenomeQuest™ for its ability to instantly locate sequence data and display it in an intuitive and easily manipulated format.
Director of Research (Anti-Infectives) and Manager, Intellectual Property

Pfizer and GenomeQuest collaborate and publish in Nature Biotech

Pfizer Inc, founded in 1849, is dedicated to better health and greater access to healthcare for people and their valued animals.

Pfizer IP attorney Guillaime Dufresne together with a research physician Laszlo Takacz and computational biologist Manuel Duval anticipated the complexity of large scale biosequence patent screening using biological search methods based on homology, a measure of evolutionary similarity and not identity, the method used to file patent claims for DNA and protein sequences. GenomeQuest scientists Jean-Jacques Codani and Henk Heus, having developed sequence comparison tools based on percent identity proposed a solution to Pfizer based on the company's proprietary "KERR" algorithm (tradename: GenePAST).

Together, GenomeQuest and Pfizer applied the technology and published in Nature Biotechnology what is now the seminal paper on percent identity searching to retrieve patent sequence records.

US patent application 20050037371